centene pac healthcare medicaid managed-care bipartisan revolving-door overbilling
related: Centene Corporation Insurance Industry Bloc Insurance Industry Elevance Anthem PAC PhRMA
Who They Are
Centene Corporation PAC (CentenePAC) is the political action committee of Centene Corporation (NYSE: CNC), the nation’s largest Medicaid managed care company. Centene manages health plans for over 15 million Medicaid enrollees across the country, generating $150B+ in annual revenue — almost entirely from government contracts. The company also operates Medicare Advantage plans, ACA marketplace plans, and military health (TRICARE) contracts, but Medicaid is the core business.
CentenePAC contributes $1-3M per cycle to federal candidates, targeting members of Congress on the Energy & Commerce, Finance, and Ways & Means committees — the panels that control Medicaid funding, managed care regulation, and ACA marketplace rules. In the 2024 cycle, Centene’s total political spending (PAC + individual contributions) was $1.8M to federal candidates and committees.
Beyond the PAC, Centene maintains a massive state-level operation: the company, its subsidiaries, top executives, and their spouses contributed more than $26.9 million to state politicians in 33 states between 2015 and 2022. This state-level spending targets governors and state legislators who award Medicaid managed care contracts — the actual source of Centene’s revenue.
The company also spends heavily on lobbying: $4.4M at the federal level in 2024, $5.2M in 2023, and $4.2M already in 2025. Since 2018, Centene has spent over $60 million on federal and state lobbying combined. Nearly two-thirds of Centene’s federal lobbyists (18 of 28 in 2024) are former government employees — the revolving door operates at industrial scale.
What They Want
Centene’s political operation has a single structural objective: protect and expand the flow of government money through Medicaid managed care. Every dollar of Centene’s revenue depends on government decisions — Medicaid funding levels, managed care contract awards, regulatory requirements, pharmacy benefit rules, and ACA marketplace subsidies. The company’s political spending is not investment in policy outcomes; it is the cost of maintaining the revenue pipeline.
Specific legislative priorities include: maintaining Medicaid expansion under the ACA, preventing cuts to Medicaid managed care reimbursement rates, shaping pharmacy benefit manager (PBM) regulations (Centene operates its own PBM), preserving favorable Medicare Advantage payment formulas, and ensuring that state-level contract award processes remain accessible to Centene despite its settlement history.
Money
Centene’s political spending is not a side operation — it is structurally integrated into the business model. The company’s $150B+ revenue is almost entirely government-funded. A 1% change in Medicaid reimbursement rates affects $1.5 billion in revenue. The $26.9M spent on state politicians between 2015-2022, the $60M+ in lobbying since 2018, and the $1-3M per cycle in PAC contributions are rounding errors against the revenue they protect. The return on investment is not measurable in percentage terms — it is the difference between the company existing and not existing.
Who They Fund
CentenePAC’s contribution pattern is aggressively bipartisan, reflecting the company’s dependence on Medicaid policy that transcends party control. In the 2024 cycle, congressional contributions split 51.5% Democratic / 48.3% Republican. When broader candidate giving (including presidential) is included, the split was 63.9% Democratic / 36.2% Republican — reflecting the Harris presidential campaign’s pull.
Key recipient patterns (2024 cycle):
The PAC overwhelmingly favors incumbents (84.6% of congressional contributions) over challengers — the goal is access to sitting committee members, not ideological outcomes. Average contributions to House members were $1,672 (D) and $2,415 (R); to Senators, $2,248 (D) and $2,707 (R). The slightly higher Republican averages reflect targeted spending on committee chairs.
Top recipients in 2024 included Kamala Harris ($225,622 from individuals), GOPAC ($150,000), DNC ($148,762), DCCC ($117,877), Project Rescue America ($100,000), and Buckeye Values PAC ($50,000 — an Ohio-focused conservative PAC reflecting Centene’s St. Louis/Midwest roots). Notable individual lawmaker recipients include Jason Smith (R-MO, Ways & Means Chair, $10,471), Brett Guthrie (R-KY, Energy & Commerce, $9,500), and Amy Klobuchar (D-MN, $17,570).
State-level giving: Centene focused its $26.9M in state giving on states where it was actively pursuing Medicaid contracts. The spending pattern maps to contract geography: states with the largest Medicaid managed care programs receive the largest contributions.
FEC Financial Summary — CentenePAC (C00397851) by Election Cycle
CentenePAC has been registered as an active monthly corporate PAC since March 19, 2004. The following table documents total receipts, disbursements, and cash on hand for each two-year cycle. The trend shows steady growth in PAC revenue through 2022, a slight contraction in the 2024 cycle, and a partial-cycle figure through February 2026.
| Cycle | Total Raised | Total Spent | Ending Cash | Notable Context |
|---|---|---|---|---|
| 2015–2016 | $1,271,654 | $939,074 | $839,245 | ACA implementation; Centene expanding Medicaid managed care footprint |
| 2017–2018 | $1,538,022 | $988,171 | $1,389,096 | ACA repeal battles; Centene lobbied to preserve Medicaid expansion |
| 2019–2020 | $1,724,438 | $1,504,798 | $1,608,737 | COVID-19 Medicaid enrollment surge; overbilling investigations begin |
| 2021–2022 | $1,922,500 | ~$1,300,000 | ~$2,200,000 | Peak overbilling settlement cycle ($939M+ across 17 states); revenue tripled |
| 2023–2024 | $1,907,487 | ~$1,625,000 | ~$1,282,612 | $150K to Trump inaugural fund; $4.4M federal lobbying; $225K to Harris |
| 2025–2026 (through Feb) | $1,143,869 | $954,755 | $1,282,612 | One Big Beautiful Bill enacted; Centene posts $6.7B net loss |
Lifetime PAC total (2015–Feb 2026): approximately $9.5M raised, $7.3M spent
Money
Centene’s PAC spending has been remarkably consistent across six cycles regardless of which party controls government — $1.3M to $1.9M raised every cycle from 2016 through 2024. This is not campaign finance as a political bet; it is an access maintenance fee. The steady bipartisan distribution (historically near-50/50) functions as insurance: whoever wins the next election, CentenePAC’s check is already on file. The fatal flaw in this strategy became visible in 2025: bipartisan access insurance does not stop a unified Republican government from passing legislation that destroys your business model. CentenePAC spent $1.9M in the 2024 cycle, including $150K to the Trump inaugural fund — and still watched the One Big Beautiful Bill enact $1 trillion in Medicaid/ACA cuts that triggered a $6.7B goodwill impairment and drove the stock to a decade low.
Donation-to-Policy Timeline
| Date | Recipient/Target | Amount | Policy Return | Time Gap |
|---|---|---|---|---|
| 2015-2022 | State politicians in 33 states | $26.9M | Centene awarded or renewed Medicaid managed care contracts in states where it gave most heavily | Ongoing |
| 2017-2022 | Lobbying: CMS and Congress on managed Medicaid issues | $60M+ (fed+state) | Medicaid managed care preserved and expanded despite ACA repeal attempts; Centene revenue grew from $48B (2017) to $144B (2022) | Concurrent |
| 2018-2023 | Federal and state lobbying during overbilling investigations | Ongoing | While settling $939M+ in overbilling claims across 17+ states, Centene retained every Medicaid contract — no state terminated the company despite proven overcharging | 0-12 months |
| 2022 | Missouri state politicians (Centene HQ state) | Millions | Despite being investigated by multiple states for Medicaid fraud, Centene maintained its Missouri Medicaid contracts | Concurrent |
| 2024 | Energy & Commerce / Ways & Means members | $300K+ PAC | H.R.5378 (Centene’s most-lobbied bill in 118th Congress) received committee attention | Months |
| 2024 | Trump inaugural fund + GOPAC | $150K+ | Positioning for favorable treatment under incoming administration on Medicaid policy | Preemptive |
| 2024-2025 | Federal lobbying | $4.4M (2024) + $4.2M (2025 YTD) | Continued access to CMS and congressional oversight of Medicaid managed care | Ongoing |
| Dec 2024 | Centene investor day — political messaging to Republicans | N/A | CEO London warned Republicans at investor presentation that Medicaid cuts would harm both patients and business sustainability. STAT News noted the prepared remarks “could be mistaken for political ads.” | 0 — preemptive |
| 2025 (Trump admin) | One Big Beautiful Bill Act | All prior political spending failed to prevent passage | $1 trillion in Medicaid/ACA cuts enacted over 10 years; 500K Centene Medicaid members lost; $6.7B goodwill impairment triggered; stock hits decade low; Centene scraps 2025 guidance | Political protection failure |
Money
The most revealing line in Centene’s timeline is not a specific donation — it is the fact that the company has settled $939M+ in Medicaid overbilling claims across 17+ states while retaining every single Medicaid contract. No state has terminated Centene despite proven overcharging. The settlements amount to a cost of doing business — Centene pays a fraction of what it overbilled, continues operating, and keeps contributing to the politicians who oversee the contracts. But the 2025 data breaks the pattern: For the first time, the political spending did not buy institutional inertia. The One Big Beautiful Bill enacted $1 trillion in Medicaid/ACA cuts despite CentenePAC’s bipartisan investment — including $150K to the Trump inaugural fund. The political spending bought access to the warning room, not to the legislative outcome. Centene executives lobbied Republicans through investor days and direct outreach; Congress passed the cuts anyway. The company’s entire bipartisan strategy was predicated on being indispensable to both parties — but a unified Republican government pursuing ideological Medicaid contraction doesn’t need Centene’s money more than it needs its own policy agenda.
The 2025 Political Protection Failure
The One Big Beautiful Bill Act, signed into law in 2025, represents the most significant test and failure of Centene’s bipartisan political strategy. Despite years of bipartisan PAC contributions, $60M+ in lobbying since 2018, and direct investment in the Trump inaugural fund, the Republican-controlled Congress enacted $1 trillion in Medicaid and ACA cuts that devastated Centene’s business.
Financial impact (2025):
- Net loss: $6.7 billion for the full year (versus profits in prior years)
- Q3 2025: $6.6 billion loss driven by non-cash goodwill impairment triggered by the One Big Beautiful Bill and stock price decline
- Q2 2025: $253 million loss as medical costs surged
- Q4 2025: $1.1 billion loss vs. $283 million profit same period prior year
- Revenue: $194.8 billion (19.4% growth) — but massive losses despite top-line growth
- Membership: Lost approximately 500,000 Medicaid members during 2025
- Stock: Hit decade low after Q2 results; share price fell over 30% through 2025
- Guidance: Scrapped full-year 2025 guidance after the bill passed
Corporate response: Centene CEO Sarah London publicly lobbied Republicans through investor day presentations — STAT News noted the prepared remarks “could be mistaken for political ads” — warning that Medicaid cuts would harm both patients and business. The company was simultaneously lobbying Congress directly and deploying its revolving-door lobbyists. None of it worked.
Contradiction
Centene donated $150,000 to the Trump inaugural fund in late 2024, positioning itself for favorable treatment under the incoming administration. By Q3 2025, the Trump-era One Big Beautiful Bill had triggered a $6.7 billion goodwill impairment and driven the stock to its lowest point in a decade. The bipartisan access strategy — nearly 50/50 giving across both parties, including direct Trump inauguration investment — did not prevent legislation that destroyed the company’s business model. The political protection Centene purchased was access and warning channels, not outcomes. When a unified government decides ideological priorities override managed care industry preferences, the access insurance fails. The $1.9M PAC cycle budget (2024) and $4.2M in lobbying (2025) could not match the political power of a governing party with a mandate and a willing Congress.
What They’ve Gotten
Contract preservation despite fraud settlements: Centene has agreed to pay $939M+ in settlements across 17+ states (Arkansas, California, Illinois, Indiana, Iowa, Kansas, Louisiana, Massachusetts, Mississippi, Nebraska, New Hampshire, Nevada, New Mexico, Ohio, Oregon, Texas, Washington) for overbilling Medicaid pharmacy programs. The California settlement alone was $215M. Despite this, Centene retains Medicaid contracts in every state where it was caught overcharging. Several states, including Georgia and Florida, have still not settled years after investigations began.
Revenue growth through political protection: Centene’s revenue grew from approximately $48B in 2017 to $144B in 2022 — tripling during a period when the company was simultaneously being investigated for Medicaid fraud across more than 20 states. This growth was enabled by continued contract awards and renewals that required political acquiescence.
Revolving door access: With 64-65% of its federal lobbyists being former government employees, Centene has built a permanent pipeline between the company and the agencies that regulate it. This is not incidental — it is the primary mechanism through which Centene maintains influence over CMS (Centers for Medicare & Medicaid Services) rulemaking and congressional oversight.
Bipartisan immunity — the historical record: By contributing nearly equally to both parties, Centene has historically ensured that no party has an institutional incentive to hold the company accountable. When Democrats control Medicaid oversight, Centene has paid them. When Republicans control it, Centene has paid them too. The overbilling settlements are processed as routine regulatory matters, not political scandals, because both parties have received the money.
The 2025 limit case: The bipartisan immunity strategy broke down when a unified Republican government enacted $1 trillion in Medicaid and ACA cuts through the One Big Beautiful Bill Act. Centene’s prior investments — including $150K to the Trump inaugural fund — did not prevent the legislation. The company’s revenue model (almost entirely government-funded managed care) was structurally incompatible with the Republican policy agenda, and the political spending could not close that gap. Centene lost $6.7B in 2025, its stock hit a decade low, and the company scrapped full-year guidance. The political protection strategy worked across 20+ years of divided government; it failed the first time a unified government prioritized ideology over incumbent industry stability.
Class Analysis
Centene Corporation is the purest case study of the Medicaid managed care extraction model: a private corporation whose entire business consists of inserting itself between government healthcare funding and patients, extracting profit from the spread. The political operation exists to maintain this intermediary position.
The overbilling pattern reveals the structural logic. Centene’s pharmacy subsidiaries overcharged Medicaid programs by reporting inflated drug costs while pocketing the difference. When caught, the company settled for a fraction of the overcharges and continued operating. The $939M+ in settlements across 17+ states is not a scandal that threatens the business — it is a line item. The political spending ensures that settlements remain financial events, not existential ones.
The 2025 limit of donor-class protection: Centene’s 2025 collapse illuminates the structural limit of the managed care extraction model. The company’s political spending bought institutional inertia — the ability to operate despite fraud settlements, to keep contracts despite overbilling, to face no existential accountability from either party. But it could not buy immunity from ideological policy shifts. When the Republican Party unified around Medicaid contraction as a governing agenda (rather than as rhetorical positioning), Centene’s bipartisan access strategy was exposed as protection against accountability, not protection against legislation. The company spent millions lobbying Congress; Congress passed the cuts anyway. The extraction model that generated $194.8B in 2025 revenue also generated a $6.7B loss because the government funding it extracted from is subject to legislative revision that no PAC budget can prevent.
Contradiction
Centene’s bipartisan giving creates a structural both-sides problem. Democrats who accept Centene money while advocating for Medicaid expansion are enabling a company that has been caught overcharging the very program they claim to protect. Republicans who accept Centene money while advocating for Medicaid cuts are funded by a company whose revenue depends on the program they claim to oppose. Neither party can hold Centene accountable without losing contributions — and neither party’s policy position threatens the fundamental extraction model. Whether Medicaid expands or contracts, Centene’s managed care intermediary position is protected by its political spending on both sides.
Enemies / Opposition
State attorneys general: At least 20 states have investigated Centene for Medicaid pharmacy overbilling. However, the investigations have uniformly resulted in settlements rather than contract terminations — the political spending insulates the company from the most serious consequence.
Healthcare reformers: Advocates for single-payer or direct government provision of Medicaid services view managed care companies like Centene as extractive intermediaries that add cost without value. The company’s overbilling settlements provide ammunition for this critique.
PBM reform advocates: Centene’s ownership of its own pharmacy benefit manager (the mechanism through which the overbilling occurred) has drawn scrutiny from both parties as part of broader PBM reform efforts.
Connected Policy Areas
Medicaid funding and managed care policy, ACA marketplace rules, Medicare Advantage payment formulas, pharmacy benefit manager regulation, state Medicaid contract procurement, healthcare industry lobbying disclosure
Sources
- OpenSecrets: Centene Corp profile — summary (Tier 1)
- OpenSecrets: Centene Corp — recipients (Tier 1)
- OpenSecrets: Centene Corp — lobbying profile (Tier 1)
- FollowTheMoney: Centene Corp state contributions (Tier 1)
- KFF Health News: Centene showers politicians with millions as it courts contracts (Tier 2)
- KFF Health News: Centene settlements with states still unfinished (Tier 2)
- Missouri Independent: Centene showers politicians with millions (Tier 2)
- Becker’s Payer: Centene spent $307M to settle overbilling in 2023 (Tier 2)
- Fierce Healthcare: Elevance Health, Centene donated to Trump inaugural fund (Tier 2)
content-readiness:: developed